Biochemical characterization of plasma in amyotrophic lateral sclerosis: Amino acid and protein composition

References

• Bruijn LI, Miller TM, Cleveland DW. Unravelling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004;27:723–49.
   PubMed Web of Science ®Google Scholar
• Malaspina A, Kaushik N, de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem. 2001;77:132–45.
   PubMed Web of Science ®Google Scholar
• Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, et al. Differential expression of inflammation and apoptosis related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 2002;80:158–67.
   PubMed Web of Science ®Google Scholar
• Perry TL, Krieger C, Hansen S, Tabatabaei A. Amyotrophic lateral sclerosis: fasting plasma levels of cysteine and inorganic sulfate are normal, as are brain contents of cysteine. Neurology. 1991;41:487–90.
   PubMedGoogle Scholar
• Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand. 1993;88:51–5.
   PubMed Web of Science ®Google Scholar
• Garrel C, Faure H, Favier A, Besson G. Decrease of plasma cysteine values in sporadic amyotrophic lateral sclerosis patients could be the early event leading to an oxidative stress. ALS Other Motor Neuron Disord. 2001; 2(Suppl 2):132–3.
   Google Scholar
• Ilzecka J, Stelmasiak Z, Solski J, Wawrzycki S, Szpetnar M. Plasma amino acids percentages in amyotrophic lateral sclerosis patients. Neurol Sci. 2003;24:293–5.
   PubMedGoogle Scholar
• Ikeda J, Kohriyama T, Nakamura S. Elevation of serum soluble E-selectin and antisulfoglucuronyl paragloboside antibodies in amyotrophic lateral sclerosis. Eur J Neurol. 2000;7:541–7.
   PubMedGoogle Scholar
• Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, Przedborski S. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002;58:1277–9.
   PubMed Web of Science ®Google Scholar
• Wilms H, Sievers J, Dengler R, Bufler J, Deuschl G, Lucius R. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol. 2003;144:139–42.
   PubMed Web of Science ®Google Scholar
• Su¨ ssmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett. 2003:57–60.
   Google Scholar
• Norgren N, Rosengren L, Stigbrand T. Elevated neurofila- ment levels in neurological diseases. Brain Res. 2003; 987:25–31.
   PubMed Web of Science ®Google Scholar
• Beuche W, Yushchenko M, Mader M, Maliszewska M, Felgenhauer K, Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 2000;11:3419–22.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Jordan K, Sathanoori R, Henry S, Wood P, Urbinelli L, et al. Identification of ALS specific biomarkers by protein profiling of cerebral spinal fluid. ALS and Other Motor Neuron Disord. 2003; 4(Suppl 1):12.
   Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. ALS and Other Motor Neuron Disord. 2000;1:293–300.
   PubMed Web of Science ®Google Scholar
• Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem. 1989;264:11539–42.
   Google Scholar
• Black JA, Dixon GH. Amino-acid sequence of alpha chains of human haptoglobins. Nature. 1968;218:736–41.
   PubMedGoogle Scholar
• Langlois MR, Delanghe JR. Biological and clinical signifi- cance of haptoglobin polymorphism in humans. Clinical Chemistry. 1996;42:1589–600.
   PubMed Web of Science ®Google Scholar
• Orrell R, Lane J, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 2004; CD002829.
   Google Scholar
• Ilzecka J, Stelmasiak Z, Solski J, Wawrzycki S, Szpetnar M. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients. Neurol Sci. 2003;24:290–2.
   Google Scholar
• Enghild JJ, Salvesen G, Brew K, Nagase H. Interaction of human rheumatoid synovial collagenase (matrix metallopro- teinase 1) and stromelysin (matrix metalloproteinase 3) with human alpha 2-macroglobulin and chicken ovostatin. Binding kinetics and identification of matrix metalloproteinase clea- vage sites. J Biol Chem. 1989;264:8779–85.
   Google Scholar
• Yushchenko M, Weber F, Mader M, Scholl U, Maliszewska M, Tumani H, et al. Matrix metalloproteinase- 9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol. 2000;110:244–51.
   PubMed Web of Science ®Google Scholar
• Kovacs DM. Alpha 2-macroglobulin in late-onset Alzheimer’s disease. Experimental Gerontology. 2000;35:473–9.
   PubMed Web of Science ®Google Scholar
• Adachi N, Shoji S. Studies of protease inhibitors in the sera of patients with amyotrophic lateral sclerosis. J Neurol Sci. 1989;89:165–8.
   Google Scholar
• Festoff BW. Occurrence of reduced alpha 2-macroglobulin and lowered protease inhibiting capacity in plasma of amyotrophic lateral sclerosis patients. Ann N Y Acad Sci. 1983;421:369–76.
   Google Scholar
• Giometto B, Argentiero V, Sanson F, Ongaro G, Tavolato B. Acute-phase proteins in Alzheimer’s disease. Eur Neurol. 1988;28:30–3.
   Google Scholar
• John HA, Purdom IF. Elevated plasma levels of haptoglobin in Duchenne muscular dystrophy: electrophoreticvariants in patients with a severe form of the disease. Electrophoresis. 1989;10:489–93.
   PubMed Web of Science ®Google Scholar
• Cucullo L, Marchi N, Marroni M, Fazio V, Namura S, Janigro D. Blood-brain barrier damage induces release of (alpha) 2-macroglobulin. Mol Cell Proteomics. 2003;2:234–41.
   PubMed Web of Science ®Google Scholar
• Finne J. Carbohydrate units of nervous tissue glycopro- teins. In: Montreuil J, Vliegenthart JFG, Schachter H, editors. Glycoproteins II. Amsterdam: Elsevier, 1997: pp.55–67.
   Google Scholar